Prostate Adenocarcinoma: Cellular and Molecular Abnormalities

Montironi R. , Schulman C.C. . Precursors of prostatic cancer: progression, regression and chemoprevention. Eur Urol. 1996; 30: 133–137.

Bostwick D.G. , Montironi R. , Sesterhenn I.A. . Diagnosis of prostatic intraepithelial neoplasia: Prostate Working Group/consensus report. Scan J Urol Nephrol Suppl. 2000; 205: 3–10.

Bostwick D.G. , Grignon D.J. , Hammond M.E. . Prognostic factors in prostate cancer. College of American Pathologists Consensus Statements 1999. Arch Pathol Lab Med. 2000; 124: 995–1000.

Bostwick D.G. , Foster C.S. , Algaba F. . Prostate tissue factors. In: Murphy G. , Denis L. , Khoury S. , eds. Prostate Cancer: Second International Consultation on Prostate Cancer. Plymouth: Plymbridge Distributors; 2000: 162–201.

Partin A.W. , Murphy G.P. , Brawer M.K. . Report on Prostate Cancer Tumor Marker Workshop 1999. Cancer. 2000; 88: 955–963.

Park S. , Shinohara K. , Grossfeld G.D. . Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol. 2001; 165: 1409–1414.

Sakr W.A. , Partin A.W. . Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology. 2001; 57: 115–120.

Sakr W.A. , Ward C. , Grignon D.J. . Epidemiology and molecular biology of early prostatic neoplasia. Mol Urol. 2000; 4: 109–113;discussion 115.

Bostwick D.G. , Amin M.B. , Dundone P. . Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol. 1993; 24: 298–310.

Bostwick D.G. , Foster C.S. . Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol. 1999; 17: 222–272.

Carter B.S. , Bova G.S. , Beaty T.H. . Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993; 150: 797–802.

Karayi M.K. , Neal D.E. , Markham A.F. . Current status of linkage studies in hereditary prostate cancer. BJU Int. 2000; 86: 659–669.

McNeal J.E. , Gleason D.F. . Gleason's classification of prostatic adenocarcinomas. Ann Pathol. 1991; 11: 163–168.

Gleason D.F. . Atypical hyperplasia, benign hyperplasia, and well-differentiated adenocarcinoma of the prostate. Am J Surg Pathol. 1985; 9: 53.

Gleason D.F. . Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992; 23: 273–279.

Gleason D.F. . Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology. 1996; 47: 289–291.

Aihara M. , Wheeler T.M. , Ohori M. . Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994; 43: 60–66;discussion 66-67.

Bastacky S.I. , Walsh P.C. , Epstein J.I. . Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol. 1993; 17: 336–341.

Egan A.J. , Bostwick D.G. . Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol. 1997; 21: 1496–1500.

Ulbright T.M. . Testis risk and prognostic factors. The pathologist's perspective. Urol Clin North Am. 1999; 26: 611–626.

Bigler S.A. , Deering R.E. , Brawer M.K. . Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993; 24: 220–226.

Lijovic M. , Fabiani M.E. , Bader J. . Prostate cancer: are new prognostic markers on the horizon? Prostate. 2000; 3: 62–65.

Mora L.B. , Moscinski L.C. , Diaz J.I. . Stage B Prostate cancer: correlation of DNA ploidy analysis with histological and clinical parameters. Cancer Control. 1999; 6: 587–591.

Diaz J.I. , Mora L.B. , Austin P.F. . Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999; 53: 931–938.

Korkolopoulou P. , Christodoulou P. , Kapralos P. . The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract. 1997; 193: 767–775.

Sasor A. , Wagrowska-Danilewicz M. , Danilewicz M. . Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Pol J Pathol JC. 2000; 51: 31–36.

Xie W. , Wong Y.C. , Tsao S.W. . Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. Prostate. 2000; 15; 44: 31–39.

Aaltomaa S. , Lipponen P. , Viitanen J. . Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy. Eur Urol. 2000; 38: 555–562.

Aaltomaa S. , Lipponen P. , Ala-Opas M. . Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol. 2001; 39: 138–144.

DiPaola R.S. , Kumar P. , Hait W.N. . State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey. N J Med. 2001; 98: 23–33.

Gao M. , Ossowski L. , Ferrari A.C. . Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol. 1999; 179: 336–346.

Gao X. , Honn K.V. . Recessive oncogenes: current status. Pathol Oncol Res. 1995; 1: 7–22.

Singh A. , Jones R.F. , Friedman H. . Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. Anticancer Res. 1999; 19: 5415–5417.

Tamboli P. , Amin M.B. , Xu H.J. . Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol. 1998; 11: 247–252.

Kwabi-Addo B. , Giri D. , Schmidt K. . Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA. 2001; 98: 11563–11568.

Stackhouse G.B. , Sesterhenn I.A. , Bauer J.J. . p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999; 162: 2046–2047.

Takayama H. , Shin M. , Nonomura N. . p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens from non-transition and transition zones. Jpn J Cancer Res. 2000; 91: 941–947.

Yu D. , Liu F. , Liang Z. . Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder [Chinese]. Zhonghua Bing Li Xue Za Zhi. 1996; 25: 202–205.

Kubota Y. , Fujinami K. , Uemura H. . Retinoblastoma gene mutations in primary human prostate cancer. Prostate. 1995; 27: 314–320.

Hu W.L. , Li Y.Q. , He H.X. . KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese. Asian J Androl. 2000; 2: 221–224.

Li P. , Nicosia S.V. , Bai W. . Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem. 2001; 276: 20444–20450.

Burton J.L. , Oakley N. , Anderson J.B. . Recent advances in the histopathology and molecular biology of prostate cancer. BJU Int. 2000; 85: 87–94.

Guo Y. , Sklar G.N. , Borkowski A. . Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 1997; 3(12 Pt 1): 2269–2274.

Fero M.L. , Rivkin M. , Tasch M. . A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996; 85: 733–744.

Matrisian L.M. , Cunha G.R. , Mohla S. . Epithelial-stromal interactions and tumor progression: meeting summary and future directions. Cancer Res. 2001; 61: 3844–3846.

Dunsmuir W.D. , Gillett C.E. , Meyer L.C. . Molecular markers for predicting prostate cancer stage and survival. BJU Int. 2000; 86: 869–878.

Thompson T.C. , Truong L.D. , Timme T.L. . Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H: 54–61.

Linja M.J. , Savinainen K.J. , Saramaki O.R. . Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001; 61: 3550–3555.

Matsuda T. , Junicho A. , Yamamoto T. . Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Res Commun. 2001; 283: 179–187.

Jones A. , Fujiyama C. , Turner K. . Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. BJU Int. 2000; 86: 80–86.

Brawer M.K. . Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer. 1996; 78: 345–349.

Kay P.A. , Robb R.A. , Bostwick D.G. . Prostate cancer microvessels: a novel method for three-dimensional reconstruction and analysis. Prostate. 1998; 37: 270–277.

Sugamoto T. , Tanji N. , Sato K. . The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization. Anticancer Res. 2001; 21: 77–88.

Mazzucchelli R. , Montironi R. , Santi-nelli A. . Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate. 2000; 45: 72–79.

Ali I.U. , Senger D.R. , Smith L.E. . Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology. 2001; 57(4 suppl 1): 143–147.

Kucuk O. , Sarkar F.H. , Sakr W. . Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Bio-markers Prev. 2001; 10: 861–868.

Diaz J.I. , Pow-Sang J.M. , Mora L.B. . Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol. 2000; 5: 149–154.

Baltaci S. , Orhan D. , Ozer G. . Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int. 2000; 85: 155–159.

Orlando C. , Gelmini S. , Selli C. . Telomerase in urological malignancy. J Urol. 2001; 166: 666–673.

Brewster S.F. , Oxley J.D. , Trivella M. . Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999; 161: 1238–1243.

Garcia R. , Bowman T.L. , Niu G. . Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20: 2499–2513.

Catlett-Falcone R. , Landowski T.H. , Oshiro M.M. . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10: 105–115.

Fernandes A. , Hamburger A.W. , Gerwin B.I. . ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer. 1999; 83: 564–570.

Lou W. , Ni Z. , Dyer K. . Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000; 42: 239–242.

Mora L.B. , Buettner R. , Seigne J. . Constitutive activation of Stat3 in human prostate tumors and cells lines: Inhibitors of Stat3 signaling block growth of prostate cancer cells. Cancer Res. 2001. In press.